TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy
Brief Summary: This project aims to: 1) evaluate the long-term effectiveness of telemedicine to detect diabetic retinopathy when compared to traditional surveillance methods, 2) identify the health belief factors related to adherence with annual diabetic eye exams, and 3) determine the cost-effectiveness of the telemedicine system from the perspective of the community clinic, the third-party payer, and the individual patient.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1
B: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Community Health Worker home visits | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Health Worker home visits | Intervention Type: BEHAVIORAL; Name: Community Health Worker home visits; Assigned to Arm(s): Behavioral, Usual Care
C: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
D: Intervention Type: BEHAVIORAL; Name: Empowerment; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy
Brief Summary: This project aims to: 1) evaluate the long-term effectiveness of telemedicine to detect diabetic retinopathy when compared to traditional surveillance methods, 2) identify the health belief factors related to adherence with annual diabetic eye exams, and 3) determine the cost-effectiveness of the telemedicine system from the perspective of the community clinic, the third-party payer, and the individual patient.


Options:
A: Arm Label: care guide; Type: EXPERIMENTAL; Interventions: Behavioral: education and care guide | Arm Label: no care guide; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education only | Intervention Type: BEHAVIORAL; Name: education and care guide; Assigned to Arm(s): care guide | Intervention Type: BEHAVIORAL; Name: education only; Assigned to Arm(s): no care guide
B: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Electronic feedback system on diabetes care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic feedback system on diabetes care; Assigned to Arm(s): Intervention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy
Brief Summary: This project aims to: 1) evaluate the long-term effectiveness of telemedicine to detect diabetic retinopathy when compared to traditional surveillance methods, 2) identify the health belief factors related to adherence with annual diabetic eye exams, and 3) determine the cost-effectiveness of the telemedicine system from the perspective of the community clinic, the third-party payer, and the individual patient.


Options:
A: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: Control; Type: OTHER; Interventions: Other: Control | Arm Label: CCH Model; Type: EXPERIMENTAL; Interventions: Other: Collaborative Connected health, (CCH) | Intervention Type: OTHER; Name: Collaborative Connected health, (CCH); Assigned to Arm(s): CCH Model | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Technology supported supervision; Type: EXPERIMENTAL; Interventions: Other: Technology supported supervision, Other: Integrated community case management | Arm Label: Community supported supervision; Type: EXPERIMENTAL; Interventions: Behavioral: Community supported supervision, Other: Integrated community case management | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated community case management | Intervention Type: OTHER; Name: Technology supported supervision; Assigned to Arm(s): Technology supported supervision | Intervention Type: BEHAVIORAL; Name: Community supported supervision; Assigned to Arm(s): Community supported supervision | Intervention Type: OTHER; Name: Integrated community case management; Assigned to Arm(s): Community supported supervision, Control arm, Technology supported supervision
D: Arm Label: SINEMA intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: SINEMA intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SINEMA intervention; Assigned to Arm(s): SINEMA intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Urinary Continence and Quality of Life in Prostate Cancer Patients
Brief Summary: This intervention program combines biofeedback PFME with a telephone or support group intervention to treat persistent urinary incontinence (UI). The study's primary aims are to improve continence, quality of life, and mood through enhancing adherence to PFME and self-management of incontinence symptoms. The secondary aims are to examine the physiological effects and cost effectiveness of the proposed interventions.


Options:
A: Arm Label: PILATES; Type: EXPERIMENTAL; Interventions: Other: PILATES | Arm Label: PFMT and AES; Type: ACTIVE_COMPARATOR; Interventions: Other: PFMT and AES | Intervention Type: OTHER; Name: PILATES; Assigned to Arm(s): PILATES | Intervention Type: OTHER; Name: PFMT and AES; Assigned to Arm(s): PFMT and AES
B: Arm Label: Kegel exercise education; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Extracorporeal biofeedback device; Type: EXPERIMENTAL; Interventions: Device: Extracorporeal biofeedback device (Any Kegel) | Intervention Type: DEVICE; Name: Extracorporeal biofeedback device (Any Kegel); Assigned to Arm(s): Extracorporeal biofeedback device
C: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE) | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE) | Intervention Type: DEVICE; Name: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE); Assigned to Arm(s): Group 1, Group 2
D: Arm Label: BF+SUPPORT; Type: EXPERIMENTAL; Interventions: Behavioral: BF+SUPPORT | Arm Label: BF+PHONE; Type: EXPERIMENTAL; Interventions: Behavioral: BF+PHONE | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: BF+SUPPORT; Assigned to Arm(s): BF+SUPPORT | Intervention Type: BEHAVIORAL; Name: BF+PHONE; Assigned to Arm(s): BF+PHONE

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.


Options:
A: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
B: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo
C: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: AIN457 150 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Intervention Type: DRUG; Name: secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: placebo to secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo, placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.


Options:
A: Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 5mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 10mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5mg BID CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10mg BID CP-690,550
B: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Arm Label: AIN457 150 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Intervention Type: DRUG; Name: secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: placebo to secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo, placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CNTO 1959; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: CNTO 1959; Assigned to Arm(s): CNTO 1959
B: Arm Label: TEPSO socks; Type: EXPERIMENTAL; Interventions: Device: TEPSO cloth | Arm Label: Standard socks; Type: PLACEBO_COMPARATOR; Interventions: Device: Standard cloth | Intervention Type: DEVICE; Name: TEPSO cloth; Assigned to Arm(s): TEPSO socks | Intervention Type: DEVICE; Name: Standard cloth; Assigned to Arm(s): Standard socks
C: Arm Label: AIN457 150mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: etanercept | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo, Etanercept, Placebo | Intervention Type: DRUG; Name: secukinumab (AIN457); Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept
D: Arm Label: AIN457 150 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Intervention Type: DRUG; Name: secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: placebo to secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo, placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of lower doses of primaquine compared to the dose recommended by the WHO for reducing P. falciparum gametocytes in the infected human host to prevent transmission of falciparum malaria to the anopheles mosquito vector.


Options:
A: Arm Label: CQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ) | Arm Label: CQ+PQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ), Drug: primaquine (PQ) | Arm Label: CQ + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: Chloroquine (CQ) | Arm Label: SP; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP) | Arm Label: SP + PQ; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP), Drug: primaquine (PQ) | Arm Label: SP + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: sulphadoxine-pyrimethamine (SP) | Intervention Type: DRUG; Name: artesunate (AS); Assigned to Arm(s): CQ + AS, SP + AS | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine (SP); Assigned to Arm(s): SP, SP + AS, SP + PQ | Intervention Type: DRUG; Name: Chloroquine (CQ); Assigned to Arm(s): CQ, CQ + AS, CQ+PQ | Intervention Type: DRUG; Name: primaquine (PQ); Assigned to Arm(s): CQ+PQ, SP + PQ
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)
C: Arm Label: 3 day therapy; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin piperaquine | Arm Label: 2 day therapy; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin piperaquine | Intervention Type: DRUG; Name: Dihydroartemisinin piperaquine; Assigned to Arm(s): 2 day therapy, 3 day therapy
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of lower doses of primaquine compared to the dose recommended by the WHO for reducing P. falciparum gametocytes in the infected human host to prevent transmission of falciparum malaria to the anopheles mosquito vector.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: primaquine (PQ) plus SP+AS | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine (SP) plus artesunate (AS); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: primaquine (PQ) plus SP+AS; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
C: Arm Label: dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Dihydroartemisininpiperaquine primaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine + primaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine + primaquine; Assigned to Arm(s): Dihydroartemisininpiperaquine primaquine
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of lower doses of primaquine compared to the dose recommended by the WHO for reducing P. falciparum gametocytes in the infected human host to prevent transmission of falciparum malaria to the anopheles mosquito vector.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: primaquine (PQ) plus SP+AS | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine (SP) plus artesunate (AS); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: primaquine (PQ) plus SP+AS; Assigned to Arm(s): 2
D: Arm Label: dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Dihydroartemisininpiperaquine primaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine + primaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine + primaquine; Assigned to Arm(s): Dihydroartemisininpiperaquine primaquine

Answer: A